StreetAlpha.app
Home › Stocks › HURA

TuHURA Biosciences, Inc. (HURA)

$1.40
▲ +5.26%
LAST CLOSE · NOV 17

TuHURA Biosciences develops experimental cancer treatments for patients whose tumors resist immunotherapy, based in Tampa, Florida. It last closed at $1.40 on Nov 17, up 5.26% on the day.

AI Auto Pilots
Is HURA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$29.9M
EPS (diluted)
−$0.50
Free cash flow
−$23.8M
Valuation
Market cap
$92.1M
65.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.9M
At Sep 30
Debt
$9.2M
At Sep 30
Shareholder equity
$19.0M
Shares outstanding
65.8M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From HURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated HURA in the past 90 days.
Average 12-month target
No price targets on HURA in the past 90 days.
Latest rating changes
CitizensReiterated
Aug 18Buy$9
CitizensInitiated
Apr 27Buy$9
DateFirmActionRatingPrice target
Aug 18CitizensReiteratedBuy$9
Apr 27CitizensInitiatedBuy$9
Loading…

Technical Analysis

HURA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 25% below its 20 day and 35% below its 50 day average. It is 45% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $1.38, and the nearest resistance the Pivot R1 at $1.45.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 11.3%/day
Key levels
$3.4352 week high+145.0%
$2.16Swing high (Sep 14)+54.3%
$2.05100 day average+46.4%
$2.03200 day average+45.0%
$1.8950 day average+35.0%
$1.7520 day average+25.0%
$1.45Pivot R1+3.6%
$1.40Last close
$1.38Pivot−1.4%
$1.32Pivot S1−5.7%
$0.4152 week low−70.7%
Indicators
RSI (14)34.69Weak, oversold below 30Neutral
MACD-0.15Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)21.8Weak trend
Williams %R-84.0Oversold below −80, overbought above −20Oversold
CCI (20)-112.9Oversold below −100, overbought above 100Oversold
Rate of change−15.4%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HURA

What happened before

See how HURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow HURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in HURA in the last 90 days.

Loading…

See today’s whale options flow across the market →

HURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼19 buying vs 57 selling
  • ▼Held by funds -3.7 pts
  • ▼Funds holding -13
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7790−14.4%
In funds' top 1000–
Held by funds10.0%13.7%−3.7 pts
New / increased7 / 1224 / 16−52.5%
Reduced / sold out39 / 1832 / 21+7.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HURA is in one of them and how their past HURA trades turned out.

HURA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HURA in an article yet. Here's the latest on the wider market.

HURA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 9
Who traded HURA · since 2024
Latest 5 filings
$50K – $100KTraded Jul 13, 2025Filed Aug 9, 2025
$1K – $15KTraded Nov 25, 2024Filed Jan 7, 2025
$100K – $250KTraded Oct 18, 2024Filed Nov 21, 2024
Laurel LeeExchange
$100K – $250KTraded Oct 18, 2024Filed Nov 21, 2024
$100K – $250KTraded May 6, 2024Filed May 25, 2024
PersonTypeAmountTradedFiledDelay
Laurel LeeR · FLBuy$50K – $100KJul 13, 2025Aug 9, 202527 d
Laurel LeeR · FLBuy$1K – $15KNov 25, 2024Jan 7, 202543 d
Laurel LeeR · FLBuy$100K – $250KOct 18, 2024Nov 21, 202434 d
Laurel LeeR · FLExchange$100K – $250KOct 18, 2024Nov 21, 202434 d
Laurel LeeR · FLBuy$100K – $250KMay 6, 2024May 25, 202419 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About TuHURA Biosciences

TuHURA Biosciences is a clinical stage company based in Tampa, Florida, that develops cancer treatments. Its lead candidate, IFx-2.0, is injected into tumors and is designed to make cancer cells look like bacteria so the immune system attacks them. It is aimed at patients whose cancers do not respond to checkpoint inhibitor drugs. The company is also developing TBS-2025, an antibody for acute myeloid leukemia, and early-stage drugs that target cells which suppress the immune system. Its candidates are not yet approved for sale.

Headquarters
Tampa, FL